#USA #New York #Pomerantz LLP #TriSalus Life Sciences #TLSI

Pomerantz Law Firm Investigates TriSalus Life Sciences Inc.

In a significant development for investors of TriSalus Life Sciences Inc. (NASDAQ: TLSI), the Pomerantz Law Firm has announced it is investigating potential claims related to securities fraud and other unlawful business practices. This news comes after recent financial disclosures revealed troubling performance metrics, leading to a sharp decline in the company's stock price.

Background

TriSalus Life Sciences Inc. focuses on developing innovative therapies for treating solid tumors. However, the recent financial report for the first quarter of 2026 painted a less-than-rosy picture. The company reported revenues of $8.90 million, representing a 2.92% decrease compared to the same quarter last year. More alarmingly, TriSalus revised its full-year revenue forecast downward by $5.5 million, now projecting revenue between $54 million and $57 million.

During an earnings call, executives from TriSalus cited lower revenues from their commercial expansion efforts as well as delays in FDA approvals for their product, TriNav Advance, as key factors in this disappointing guidance. Specifically, the management disclosed that FDA clearance for TriNav Advance had experienced a delay of approximately five months beyond the 30-day MDUFA review period. This news prompted investors to react, resulting in a significant drop in the company's stock price, which plummeted by $1.89, or 41.56%, closing at $2.67 per share on May 13, 2026.

The Investigation

Pomerantz LLP is urging affected investors to contact Danielle Peyton, who is leading the investigation. The firm, renowned for its expertise in corporate and securities class-action litigation, aims to determine whether TriSalus and its top executives have violated securities laws. Founded by the late Abraham L. Pomerantz, the firm has a prestigious history in protecting the rights of investors against fraud and corporate mismanagement.

As part of the investigation, the firm will look into whether the statements made by TriSalus's management were misleading or whether they failed to disclose critical information that could have affected investors' decision-making. Given the sharp decline in stock price coupled with the recent financial downturn, this inquiry may pave the way for a potential class-action lawsuit.

Pomerantz is well-regarded in the legal industry and has successfully recovered substantial damages on behalf of investors in the past. Their commitment to fighting for justice in securities fraud cases is helping to establish accountability among corporate leaders.

Conclusion

Investors affiliated with TriSalus Life Sciences should be attentive to this unfolding situation. The firm’s investigation may provide critical insights into the company's business practices and potential misconduct. Interested parties can find further information and join the class action through Pomerantz's official communication channels.

For additional communication, Danielle Peyton can be reached directly at [email protected] or via phone at 646-581-9980, ext. 7980. As developments unfold, both current and potential investors are encouraged to stay informed about the implications of this investigation on their investments and the future of TriSalus Life Sciences Inc.